The agreement stems from the exclusive license to Amsterdam Molecular Therapeutics (AMT) from Digna Biotech to commercialize all gene therapy products resulting from the R&D activities performed at the Center for the Study of Applied Medicine (CIMA) at the University of Navarra, Spain. The insulin-like growth factor (IGF-1) program is the first initiated under that agreement.
Ronald Lorijn, CEO of AMT, said: “We are very pleased with our agreement with CIMA, which gives us access to programs that are already well-advanced and that have tremendous potential. AMT is fully dedicated and equipped to add this new program to its product pipeline and plans to start the necessary pre-clinical studies including a full toxicology program next year.”